This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
November 3–5, 2025
Vienna Congress and Convention Center, Vienna, AustriaNovember 11–12, 2025 | Digital Partnering

Karen O'Hanlon
Chief Development Officer at Stablepharma Ltd
Speaker

Profile

Dr O'Hanlon is Chief Development Officer at Stablepharma, previously holding the position of VP of Clinical Operations at Boyds Consulting. She led the clinical development of SPVX02 in collaboration with Professor Saul Faust at the University Hospital Southampton NHS Foundation Trust/NIHR.

Karen has a PhD in Biochemistry and Molecular Biology from Manchester University and has worked in clinical drug development for over 20 years. Along with many other skills, Karen is an expert in the translation design, strategic planning and conduct of early phase clinical trials and she has worked on studies across the EU, with a focus on Vaccines and advanced therapies.